FORM 4
[ ] Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).         
 UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP OF SECURITIES
                                                                                  
 OMB APPROVAL
OMB Number: 3235-0287
Estimated average burden
hours per response... 0.5
                      
Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934 or Section 30(h) of the Investment Company Act of 1940
                      

1. Name and Address of Reporting Person *

Cardama Alfonso Quintas		 2. Issuer Name and Ticker or Trading Symbol

TCR2 THERAPEUTICS INC. [ TCRR ] 		5. Relationship of Reporting Person(s) to Issuer (Check all applicable)

_____ Director                    _____ 10% Owner
__X__ Officer (give title below)    _____ Other (specify below)
Chief Medical Officer
(Last)          (First)          (Middle)

C/O TCR2 THERAPEUTICS, 100 BINNEY STREET		 3. Date of Earliest Transaction (MM/DD/YYYY)

11/17/2022
(Street)

CAMBRIDGE, MA 02142
(City)        (State)        (Zip)
4. If Amendment, Date Original Filed (MM/DD/YYYY)

 
 6. Individual or Joint/Group Filing (Check Applicable Line)

_X _ Form filed by One Reporting Person
___ Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1.Title of Security
(Instr. 3) 		2. Trans. Date 2A. Deemed Execution Date, if any 3. Trans. Code
(Instr. 8) 		4. Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5) 		5. Amount of Securities Beneficially Owned Following Reported Transaction(s)
(Instr. 3 and 4) 		6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4) 7. Nature of Indirect Beneficial Ownership (Instr. 4)
Code V Amount (A) or (D) Price
Common Stock         46915 D  

Table II - Derivative Securities Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivate Security
(Instr. 3)		2. Conversion or Exercise Price of Derivative Security3. Trans. Date3A. Deemed Execution Date, if any4. Trans. Code
(Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D)
(Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date7. Title and Amount of Securities Underlying Derivative Security
(Instr. 3 and 4)		8. Price of Derivative Security
(Instr. 5)		9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)10. Ownership Form of Derivative Security: Direct (D) or Indirect (I) (Instr. 4)11. Nature of Indirect Beneficial Ownership (Instr. 4)
CodeV(A)(D)Date ExercisableExpiration DateTitleAmount or Number of Shares
Stock Option (right to buy) $16.11 11/17/2022  D     5799   (1)4/10/2029 Common Stock 5799 $0.00 (2)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   1933     (4) (4)Common Stock 1933 $0.00 (2)1933 D  
Stock Option (right to buy) $16.11 11/17/2022  D     205503   (1)4/10/2029 Common Stock 205503 $0.00 (5)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   68501     (4) (4)Common Stock 68501 $0.00 (5)68501 D  
Stock Option (right to buy) $16.10 11/17/2022  D     3308   (6)12/18/2029 Common Stock 3308 $0.00 (7)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   1103     (8) (8)Common Stock 1103 $0.00 (7)1103 D  
Stock Option (right to buy) $16.10 11/17/2022  D     68792   (6)12/18/2029 Common Stock 68792 $0.00 (9)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   22931     (8) (8)Common Stock 22931 $0.00 (9)22931 D  
Stock Option (right to buy) $31.83 11/17/2022  D     4486   (10)12/9/2030 Common Stock 4486 $0.00 (11)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   816     (12) (12)Common Stock 816 $0.00 (11)816 D  
Stock Option (right to buy) $31.83 11/17/2022  D     96514   (10)12/9/2030 Common Stock 96514 $0.00 (13)0 D  
Restricted Stock Unit (right to buy)  (3)11/17/2022  A   17548     (12) (12)Common Stock 17548 $0.00 (13)17548 D  
Explanation of Responses:
(1) This cancelled option vested 25% on January 1, 2020 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.
(2) On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,933.
(3) Each restricted stock unit represents a right to receive one share of the issuer's common stock at the time of vesting for no consideration.
(4) The restricted stock units will vest 98% on December 1, 2022, and 2% on December 1, 2023.
(5) On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on April 11, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 68,501.
(6) This cancelled option vested 25% on January 1, 2021 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.
(7) On November 17, 2022, the issuer canceled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 1,103.
(8) 73% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023 and the remaining 2% will vest on December 1, 2024.
(9) On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 19, 2019. In exchange for such stock option, the reporting person received restricted stock units in the amount of 22,931.
(10) This cancelled option vested 25% on January 1, 2022 and the remaining 75% vests in 36 substantially equal monthly installments thereafter.
(11) On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 816.
(12) 48% of these RSUs will vest on December 1, 2022, 25% will vest on December 1, 2023, another 25% will vest on December 1, 2024 and the remaining 2% will vest on December 1, 2025.
(13) On November 17, 2022, the issuer cancelled, pursuant to the issuer's offer to exchange eligible options for new restricted stock units program, a stock option granted to the reporting person on December 10, 2020. In exchange for such stock option, the reporting person received restricted stock units in the amount of 17,548.

Reporting Owners
Reporting Owner Name / Address
Relationships
Director10% OwnerOfficerOther
Cardama Alfonso Quintas
C/O TCR2 THERAPEUTICS
100 BINNEY STREET
CAMBRIDGE, MA 02142

Chief Medical Officer
Signatures
/s/ Margaret Siegel as Attorney-in-Fact11/18/2022
**Signature of Reporting PersonDate
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
*If the form is filed by more than one reporting person, see Instruction 4(b)(v).
**Intentional misstatements or omissions of facts constitute Federal Criminal Violations. See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note:File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB control number.
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jun 2024 to Jul 2024 Click Here for more TCR2 Therapeutics Charts.
TCR2 Therapeutics (NASDAQ:TCRR)
Historical Stock Chart
From Jul 2023 to Jul 2024 Click Here for more TCR2 Therapeutics Charts.